What is the recommended dosage of capmatinib each time?

The recommended standard dose of capmatinib is based on studies of its pharmacokinetics, efficacy and safety. According to the current approved labeling by international drug regulatory agencies (such as FDA and EMA), the drug is recommended for the treatment of patients with metastatic non-small cell lung cancer with MET exon 14 skipping mutations. Its standard adult dose is 400 mg twice daily, administered orally.

It is recommended to take the medicine on an empty stomach or with food. This is mainly due to its high bioavailability in the body and is not significantly affected by the gastric acid environment after meals. However, it should be emphasized that capmatinib is a highly active molecule drug, so it is important to maintain dose consistency and avoid missing doses, taking them by mistake, or changing the dose yourself to avoid affecting the efficacy or increasing the risk of toxicity.

In actual clinical application, some patients may need dose adjustment due to abnormal liver function, interstitial lung disease, gastrointestinal reactions or other serious adverse events. At this time, doctors usually gradually adjust the dose to 200 mg or 150 mg twice a day based on the patient's constitution and the severity of adverse reactions. Dosage adjustment must follow strict medical procedures and cannot be performed without authorization. At the same time, for patients with impaired liver and renal function, the initial dose needs to be set more carefully, especially for patients with moderate or severe liver dysfunction, who may need additional dose reduction or more frequent monitoring of blood drug concentrations.

In addition, the dosing regimen of capmatinib generally recommends continued use until disease progression or the patient cannot tolerate the side effects. If you need to combine other drugs during treatment, such as antibiotics, antiviral drugs, anti-epileptic drugs, etc., you need to pay attention to drug-drug interactions. Because capmatinib is a metabolic substrate of CYP3A, certain enzyme inducers or inhibitors may affect its plasma concentration.

Reference materials:https://www.drugs.com/mtm/capmatinib.html